In recent years, there has been a general trend in the United States of pharmacy benefit managers managing the cost of obesity and diabetes care to exert pressure on the price of Novo Nordisk’s and competitors’ products. Furthermore, 2025 saw the finalisation of the second round of negotiations with the US administration on Medicare Part D drug prices under the Inflation Reduction Act. Included in these negotiations were semaglutide based products Ozempic®, Rybelsus® and Wegovy® from Novo Nordisk. The negotiated price for the products in Medicare Part D will go into effect in 2027.
All entries for: Novo Nordisk
October 16, 2025
Novo Nordisk
Layoffs
Denmark
50,001+ employees
As part of its restructuring that includes cutting about 9,000 employees globally, Novo Nordisk is laying off U.S. employees this week and continuing into next week. Reuters noted that based on an email it received, affected departments include HR, clinical development, rare diseases, medical and regulatory, legal, ethics and compliance, marketing and sales, finance and public affairs.
Disease Area: Chronic Disease, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
October 14, 2025
Novo Nordisk
Layoffs
Denmark
50,001+ employees
Almost all of Novo’s 250 cell therapy employees will be laid off, Fierce reported, citing the Danish outlet Borsen.
Disease Area: Chronic Disease, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
September 19, 2025
Novo Nordisk
Layoffs
Denmark
50,001+ employees
Novo Nordisk will let go of 263 employees at its U.S. headquarters in Plainsboro, New Jersey, effective Dec. 31.
Disease Area: Chronic Disease, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
September 11, 2025
Novo Nordisk
Layoffs
Denmark
50,001+ employees
Novo Nordisk is cutting some 9,000 staff across its global operations, including around 5,000 in Denmark, in a bid to generate around $1.25 billion in annualized savings through 2026. The layoffs, which amount to an 11% headcount reduction, will begin “immediately,” and Novo expects to incur 9 billion Danish Kroner ($1.41 billion) in one-off costs, which will reflect in third-quarter 2025 results.
Disease Area: Chronic Disease, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule